Proveca announces exclusive worldwide development and license agreement with Catalent for its Zydis® ODT technology for use with Glycopyrrolate

This press release is intended for investors only.

10th February 2026 - Proveca, a pharmaceutical company specialising in medicines for children, announced today that it has entered into an exclusive worldwide development and license agreement with Catalent, a leading global contract development and manufacturing organization (CDMO), to access Catalent’s proprietary Zydis® orally disintegrating tablet (ODT) technology for use with Glycopyrrolate (also known as Glycopyrronium).

The agreement supports Proveca’s commitment to develop improved treatment options for paediatric patients suffering from chronic sialorrhoea (excessive drooling), a condition commonly associated with neurological disorders, which can significantly reduce quality of life for both patients and their caregivers. Glycopyrrolate is a well-established anticholinergic medicine that, in addition to its use in sialorrhea, is approved in different geographies, formulations and routes of administration for other indications including peptic ulcer disease, hyperhidrosis (excessive sweating), perioperative reduction of secretions and as an adjunct in anesthesia and respiratory care.”

Proveca currently markets Sialanar® (glycopyrronium) oral solution, an established medicine for the symptomatic treatment of severe sialorrhoea in children and adolescents aged 3 years and older with chronic neurological disorders. Through this agreement, Proveca aims to develop a new fast-dissolving ODT formulation of glycopyrrolate using Catalent’s Zydis® technology, to offer sialorrhoea patients an alternative oral dosage form.

Zydis® ODT is an established drug delivery technology that dissolves in less than three seconds on the tongue without water, offering ease of administration and the potential to simplify daily care routines, while maintaining the therapeutic benefits patients depend on.

“Proveca are delighted to announce this exclusive agreement with Catalent for its Zydis® ODT technology to support the expansion of our glycopyrrolate product offering (building on our Sialanar® oral liquid) across Europe, USA and other Worldwide markets. We are excited to work on our plans to expand the product’s license to include additional indications” , said Dr Simon Bryson, CEO, Proveca.

“Catalent has a strong history of partnering to accelerate the delivery of innovative therapies to market, and we’re excited to collaborate with Proveca to help meet the needs of pediatric patients with sialorrhoea,” said Kate Barnett, General Manager, Zydis®. “Together, we’re working to support a patient-friendly treatment experience that has the potential to ease daily treatment challenges and support better quality of life for patients and their caregivers.”